drugs . fda received an increasing number of advertising and promotional materials for examination between fiscal year 2004 and fiscal year 2008 , but agency officials told us that staff were unable to review all materials submitted . fda received an increasing number of voluntary draft submissions each year , with 429 submissions in fiscal year 2004 and 634 submissions in fiscal year 2008 . in addition to receiving these voluntary draft submissions , fda received a substantially greater and increasing number of final materials that manufacturers were required to submit . fda received 45,394 final materials in fiscal year 2004 and 70,509 final materials in fiscal year 2008 â€” an increase of 55 percent over the time period . fda officials told us that the agency was unable to examine all of the promotional materials for drugs it received between fiscal year 2004 and fiscal year 2008 because it lacked the resources to do so . the number of full - time equivalent ( fte ) staff supporting fda's oversight of drug promotions grew 26 percent from 35 ftes in fiscal year 2004 to 44 ftes in fiscal year 2008 . over this period , the number of ftes supporting the agency's oversight of biologics promotions increased from 4 ftes to 6 ftes , while the number of ftes supporting the agency's review of devices promotions decreased from 5 ftes to 4 ftes . because counts of ftes do not include contractors , these data do not fully represent fda's staffing resources for these activities . in addition to the contact named above , geri redican - bigott , assistant director ; kye briesath ; cathy hamann ; rebecca hendrickson ; richard lipinski ; emily loriso ; kevin milne ; lisa motley ; and patricia roy made key contributions to this report . information technology: fda needs to establish key plans and processes for guiding systems modernization efforts . gao - 09-523 . funding for fda's oversight of drug advertising and promotion increased 167 percent from about $4 million in fiscal year 2004 to about $10 million in fiscal year 2008 . funding for fda's oversight of biologics advertising and promotion also increased from $546,000 in fiscal year 2004 to $925,000 in fiscal year 2008 . in contrast , funding for the agency's oversight of devices advertising and promotion decreased from $590,000 in fiscal year 2004 to $452,000 in fiscal year 2008 . because counts of ftes do not include contractors , these data do not fully represent fda's staffing resources for these activities . june 2 , 2009 . high - risk series: an update . gao - 09-271 . washington , d.c.: january 2009 . food safety: improvements needed in fda oversight of fresh produce . gao - 08-1047 . washington , d.c.: september 26 , 2008 . drug safety: better data management and more inspections are needed to strengthen fda's foreign drug inspection program . gao - 08-970 . washington , d.c.: september 22 , 2008 . food labeling: fda needs to better leverage resources , improve oversight , and effectively use available data to help consumers select healthy foods . gao - 08-597 . washington , d.c.: september 9 , 2008 . prescription drugs: fda's oversight of the promotion of drugs for off - label uses .